Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours.

NCT03568656 is registered in ClinicalTrials.gov with CellCentric Ltd. as lead sponsor.

NCT NCT03568656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03568656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours.
Lead sponsor
CellCentric Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
July 23, 2018
Completion date
July 6, 2025
Enrollment
219 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, metastatic breast cancer, metastatic castration-resistant prostate cancer, non-small cell lung cancer